jcm-logo

Journal Browser

Journal Browser

Advances in Interventional Cardiology and Vascular Medicine

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (1 December 2017) | Viewed by 72122

Special Issue Editors


E-Mail Website
Guest Editor
1. Division of Cardiovascular Medicine, University of Connecticut, Farmington, CT 06105, USA
2. Division of Cardiovascular Medicine, VACT Healthcare System, West Haven, CT 06111, USA
3. Division of Cardiovascular Medicine, Saint Francis Hospital, Hartford, CT 06205, USA
Interests: interventional cardiology; nuclear cardiology; high-risk angioplasty; mechanical cardiac support; endothelial dysfunction; spontaneous coronary dissection

E-Mail Website
Guest Editor
Director, Cardiac Catheterization Laboratory, VA Connecticut, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA

Special Issue Information

Dear Colleagues,

We are excited to serve as the Guest Editors for a Special Issue of the Journal of Clinical Medicine, dedicated to advances in interventional cardiology and vascular medicine” to be published in January-February 2018. This Special Issue, titled “Advances in Interventional Cardiology and Vascular Medicine” will focus on current advances in coronary and peripheral vascular disease and intervention.

There has been significant progress in the field of interventional cardiology from newer devices to newer applications of technology, resulting in improved cardiovascular outcomes. The goal of this Special Issue would be to update the practicing clinician and provide a comprehensive collection of review articles and editorials.

To this end, we would like to invite state-of-the-art reviews, including reviews of new technology and therapeutics, as well as original research in this area will be considered for inclusion in this issue. Examples include history and evolution of interventional techniques, reviews of specific devices (i.e., stent technology, atherectomy devices, and robotics), medical therapy (i.e., anti-platelet therapy in coronary or peripheral intervention), specific clinical problems (i.e., risk/benefit in revascularization in stable CAD or stable claudication), advances in the management of challenging coronary anatomy and interventional techniques in the management of heart failure, venous insufficiency, peripheral arterial diseases and pulmonary embolism.

We highly encourage submission of manuscripts that would integrate vascular biology and medicine especially as it relates to imaging plaque vulnerability and future directions in vascular imaging.

The deadline for submission of these articles to the journal is 1 December, 2017. We look forward to your submissions!

Dr. Aseem Vashist
Dr. Steven E. Pfau
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (11 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

4 pages, 156 KiB  
Editorial
Endotheliitis and Endothelial Dysfunction in Patients with COVID-19: Its Role in Thrombosis and Adverse Outcomes
by Wassim Mosleh, Kai Chen, Steven E. Pfau and Aseem Vashist
J. Clin. Med. 2020, 9(6), 1862; https://doi.org/10.3390/jcm9061862 - 15 Jun 2020
Cited by 61 | Viewed by 6359
Abstract
Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), emerging in Wuhan, China and developing into a pandemic with rapidly emerging cardiovascular manifestations [...] Full article
(This article belongs to the Special Issue Advances in Interventional Cardiology and Vascular Medicine)

Review

Jump to: Editorial

14 pages, 1147 KiB  
Review
Coronary Physiology in the Cardiac Catheterization Laboratory
by Samit M. Shah and Steven E. Pfau
J. Clin. Med. 2019, 8(2), 255; https://doi.org/10.3390/jcm8020255 - 18 Feb 2019
Cited by 10 | Viewed by 6872
Abstract
Coronary angiography has been the principle modality for assessing the severity of atherosclerotic coronary artery disease for several decades. However, there is a complex relationship between angiographic coronary stenosis and the presence or absence of myocardial ischemia. Recent technological advances now allow for [...] Read more.
Coronary angiography has been the principle modality for assessing the severity of atherosclerotic coronary artery disease for several decades. However, there is a complex relationship between angiographic coronary stenosis and the presence or absence of myocardial ischemia. Recent technological advances now allow for the assessment of coronary physiology in the catheterization laboratory at the time of diagnostic coronary angiography. Early studies focused on coronary flow reserve (CFR) but more recent work has demonstrated the physiologic accuracy and prognostic value of the fractional flow reserve (FFR) and instantaneous wave free ratio (iFR) for the assessment of coronary artery disease. These measurements have been validated in large multi-center clinical trials and have become indispensable tools for guiding revascularization in the cardiac catheterization laboratory. The physiological assessment of chest pain in the absence of epicardial coronary artery disease involves coronary thermodilution to obtain the index of microcirculatory resistance (IMR) or Doppler velocity measurement to determine the coronary flow velocity reserve (CFVR). Physiology-based coronary artery assessment brings “personalized medicine” to the catheterization laboratory and allows cardiologists and referring providers to make decisions based on objective findings and evidence-based treatment algorithms. The purpose of this review is to describe the theory, technical aspects, and relevant clinical trials related to coronary physiology assessment for an intended audience of general medical practitioners. Full article
(This article belongs to the Special Issue Advances in Interventional Cardiology and Vascular Medicine)
Show Figures

Figure 1

10 pages, 1091 KiB  
Review
Update in Spontaneous Coronary Artery Dissection
by Joseph Ingrassia, Daniel Diver and Aseem Vashist
J. Clin. Med. 2018, 7(9), 228; https://doi.org/10.3390/jcm7090228 - 21 Aug 2018
Cited by 9 | Viewed by 8191
Abstract
There has been increased awareness in the understanding and recognition of spontaneous coronary artery disease. Diagnosing this condition is of paramount importance as the treatment strategy differs greatly from traditional acute coronary syndrome patient. We review here the current state of management of [...] Read more.
There has been increased awareness in the understanding and recognition of spontaneous coronary artery disease. Diagnosing this condition is of paramount importance as the treatment strategy differs greatly from traditional acute coronary syndrome patient. We review here the current state of management of spontaneous coronary artery disease. Full article
(This article belongs to the Special Issue Advances in Interventional Cardiology and Vascular Medicine)
Show Figures

Figure 1

10 pages, 2713 KiB  
Review
Percutaneous Left Main Coronary Intervention: A Review of Plaque Modification in Left Main Percutaneous Coronary Intervention
by Chirag A. Shah and Steven E. Pfau
J. Clin. Med. 2018, 7(7), 180; https://doi.org/10.3390/jcm7070180 - 23 Jul 2018
Cited by 6 | Viewed by 5126
Abstract
Left main coronary artery (LMCA) stenosis has long been recognized as a marker of increased morbidity and mortality. Current treatment algorithms for LMCA stenosis consider both percutaneous coronary intervention (PCI) with drug eluting stents (DES) and coronary bypass surgery, each with advantages based [...] Read more.
Left main coronary artery (LMCA) stenosis has long been recognized as a marker of increased morbidity and mortality. Current treatment algorithms for LMCA stenosis consider both percutaneous coronary intervention (PCI) with drug eluting stents (DES) and coronary bypass surgery, each with advantages based on individual patient characteristics. Since the LMCA is the largest artery in the coronary tree, plaque volume and calcification is greater than other coronary segments and often extends to the distal bifurcation segment. In LMCA bifurcation lesions, larger minimal stent area is strongly associated with better outcome in the DES era. Plaque modification strategies such as rotational, orbital, or laser atherectomy are effective mechanisms to reduce plaque volume and alter compliance, facilitating stent delivery and stent expansion. We present a case of a calcified, medina class 1,1,1 LMCA lesion where intravascular ultrasound (IVUS) and orbital atherectomy were employed for optimal results. In this context, we review the evidence of plaque modification devices and the rationale for their use in unprotected left main PCI. Full article
(This article belongs to the Special Issue Advances in Interventional Cardiology and Vascular Medicine)
Show Figures

Figure 1

8 pages, 676 KiB  
Review
Coronary Stents: History, Design, and Construction
by Torrey Schmidt and J. Dawn Abbott
J. Clin. Med. 2018, 7(6), 126; https://doi.org/10.3390/jcm7060126 - 29 May 2018
Cited by 85 | Viewed by 10966
Abstract
The history of percutaneous coronary intervention (PCI) is marked by rapid technological advancements that have taken place over the past 40 years. After a period of balloon angioplasty, which was marred by risk of abrupt vessel closure and vessel recoil, balloon expandable metal [...] Read more.
The history of percutaneous coronary intervention (PCI) is marked by rapid technological advancements that have taken place over the past 40 years. After a period of balloon angioplasty, which was marred by risk of abrupt vessel closure and vessel recoil, balloon expandable metal alloy stents were the mainstay of PCI. The introduction of drug eluting stents (DES) targeted in-stent restenosis, a common mode of stent failure, and ushered in the current PCI era. Since the first generation of DES, advances in polymer science and stent design have advanced the field. The current generation of DES has thin struts, are highly deliverable, have biocompatible or absorbable polymers, and outstanding safety and efficacy profiles. In this review, we discuss the technological advancements in stent development, design, and construction, with an emphasis on balloon expandable stents. The aspects of stent properties, metal alloys, bioresorbable vascular scaffolds, drug elution, and polymers will be covered. Full article
(This article belongs to the Special Issue Advances in Interventional Cardiology and Vascular Medicine)
Show Figures

Figure 1

9 pages, 222 KiB  
Review
Review of the Latest Percutaneous Devices in Critical Limb Ischemia
by Leila Haghighat, Sophia Elissa Altin, Robert R. Attaran, Carlos Mena-Hurtado and Christopher J. Regan
J. Clin. Med. 2018, 7(4), 82; https://doi.org/10.3390/jcm7040082 - 14 Apr 2018
Cited by 8 | Viewed by 4774
Abstract
Critical limb ischemia (CLI) is a terminal stage of peripheral arterial disease that, in the absence of intervention, may lead to lower extremity amputation or death. Endovascular interventions have become a first-line approach to the management of CLI and have advanced considerably within [...] Read more.
Critical limb ischemia (CLI) is a terminal stage of peripheral arterial disease that, in the absence of intervention, may lead to lower extremity amputation or death. Endovascular interventions have become a first-line approach to the management of CLI and have advanced considerably within the past decade. This review summarizes the types of percutaneous devices and the techniques that are available for the management of CLI and the data supporting their use. These include devices that establish and maintain vessel patency, including percutaneous transluminal angioplasty, drug-coated balloons, bare metal stents, drug-eluting stents, bioresorbable vascular scaffolds, and atherectomy; devices that provide protection from embolization; and, cell-based therapies. Additionally, ongoing trials with important implications for the field are discussed. Full article
(This article belongs to the Special Issue Advances in Interventional Cardiology and Vascular Medicine)
16 pages, 3207 KiB  
Review
Latest Innovations in the Treatment of Venous Disease
by Robert R. Attaran
J. Clin. Med. 2018, 7(4), 77; https://doi.org/10.3390/jcm7040077 - 11 Apr 2018
Cited by 21 | Viewed by 7815
Abstract
Venous disease is more common than peripheral arterial disease. Pathophysiologically, venous disease can be associated with obstruction, reflux, or both. A common feature in chronic venous disease is ambulatory venous hypertension. Inflammatory and pro-thrombotic mechanisms can be activated. The current therapies, including compression, [...] Read more.
Venous disease is more common than peripheral arterial disease. Pathophysiologically, venous disease can be associated with obstruction, reflux, or both. A common feature in chronic venous disease is ambulatory venous hypertension. Inflammatory and pro-thrombotic mechanisms can be activated. The current therapies, including compression, ablation, and recanalization are discussed. Full article
(This article belongs to the Special Issue Advances in Interventional Cardiology and Vascular Medicine)
Show Figures

Figure 1

23 pages, 1122 KiB  
Review
Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma
by Surya Chaturvedula, Daniel Diver and Aseem Vashist
J. Clin. Med. 2018, 7(4), 74; https://doi.org/10.3390/jcm7040074 - 9 Apr 2018
Cited by 7 | Viewed by 6301
Abstract
Percutaneous coronary intervention (PCI) with stenting for the treatment of acute coronary syndrome (ACS) is the contemporary standard of care. Such treatment is followed by dual antiplatelet therapy (DAPT) comprising of aspirin and a P2Y12 inhibitor. The efficacy of this therapy has been [...] Read more.
Percutaneous coronary intervention (PCI) with stenting for the treatment of acute coronary syndrome (ACS) is the contemporary standard of care. Such treatment is followed by dual antiplatelet therapy (DAPT) comprising of aspirin and a P2Y12 inhibitor. The efficacy of this therapy has been well established but the optimal duration of DAPT remains elusive, and has thus far attracted a prodigious deal of scientific attention. The decision regarding DAPT duration can be clinically challenging in the modern era with the evolution of newer stents, more potent antiplatelet agents, and novel anticoagulant drugs in addition to an older patient population with multiple comorbidities. Major societal guidelines have emphasized comprehensive assessment of ischemic and bleeding risk, in turn recommending individualization of DAPT duration, thus encouraging “shared decision making”. The following review is aimed at critically evaluating the available evidence to help make these crucial clinical decisions regarding duration of DAPT and triple therapy. Full article
(This article belongs to the Special Issue Advances in Interventional Cardiology and Vascular Medicine)
Show Figures

Figure 1

10 pages, 446 KiB  
Review
Safety, Efficacy and Evidence Base for Use of the Subcutaneous Implantable Cardioverter Defibrillator
by Carmen Adduci, Francesca Palano and Pietro Francia
J. Clin. Med. 2018, 7(3), 53; https://doi.org/10.3390/jcm7030053 - 11 Mar 2018
Cited by 9 | Viewed by 4391
Abstract
The trans-venous implantable cardioverter defibrillator (TV-ICD) is effective in treating life-threatening ventricular arrhythmia and reduces mortality in high-risk patients. However, there are significant short- and long-term complications that are associated with intravascular leads. These shortcomings are mostly relevant in young patients with long [...] Read more.
The trans-venous implantable cardioverter defibrillator (TV-ICD) is effective in treating life-threatening ventricular arrhythmia and reduces mortality in high-risk patients. However, there are significant short- and long-term complications that are associated with intravascular leads. These shortcomings are mostly relevant in young patients with long life expectancy and low risk of death from non-arrhythmic causes. Drawbacks of trans-venous leads recently led to the development of the entirely subcutaneous implantable cardioverter defibrillator (S-ICD). The S-ICD does not require vascular access or permanent intravascular defibrillation leads. Therefore, it is expected to overcome many complications associated with conventional ICDs. This review highlights data on safety and efficacy of the S-ICD and is envisioned to help in identifying the role of this device in clinical practice. Full article
(This article belongs to the Special Issue Advances in Interventional Cardiology and Vascular Medicine)
Show Figures

Figure 1

8 pages, 657 KiB  
Review
Update on the Non-Pharmacological Management of Stroke Prevention in Patients with Atrial Fibrillation
by Aneesh Tolat and Neal Lippman
J. Clin. Med. 2018, 7(2), 32; https://doi.org/10.3390/jcm7020032 - 12 Feb 2018
Cited by 2 | Viewed by 4412
Abstract
Non-surgical left atrial appendage occlusion has emerged as an alternative to anticoagulant therapy in the management of stroke risk in patients with atrial fibrillation. This review reports on some of the more common devices that are currently being used to manage patients in [...] Read more.
Non-surgical left atrial appendage occlusion has emerged as an alternative to anticoagulant therapy in the management of stroke risk in patients with atrial fibrillation. This review reports on some of the more common devices that are currently being used to manage patients in this challenging group. Full article
(This article belongs to the Special Issue Advances in Interventional Cardiology and Vascular Medicine)
Show Figures

Figure 1

15 pages, 3984 KiB  
Review
Robotic-Assisted Percutaneous Coronary Intervention: Rationale, Implementation, Case Selection and Limitations of Current Technology
by Michael Ragosta and Kanwar P. Singh
J. Clin. Med. 2018, 7(2), 23; https://doi.org/10.3390/jcm7020023 - 30 Jan 2018
Cited by 15 | Viewed by 5356
Abstract
Interventional cardiologists have witnessed an explosive growth in the field. A wide array of percutaneous procedures allow us to treat numerous cardiac conditions less invasively. However, the way we work has changed very little over the past decades. We continue to stand at [...] Read more.
Interventional cardiologists have witnessed an explosive growth in the field. A wide array of percutaneous procedures allow us to treat numerous cardiac conditions less invasively. However, the way we work has changed very little over the past decades. We continue to stand at the tableside for prolonged periods of time, exposing ourselves to the very real risks of radiation exposure as well as to the associated orthopedic injuries from radiation protection. The precision of our procedures is limited by the distance from the fluoroscopic images and, furthermore, patients are potentially at risk from operator fatigue caused by a physician standing at the table for prolonged periods while wearing cumbersome radiation protection gear. Robotic-assisted coronary intervention removes the operator from the radiation field and has been shown to markedly reduce operator exposure as well as allow for more precise positioning of balloons and stents. This technology holds great promise for making interventional procedures safer and more comfortable for the operators as well as reducing fatigue, potentially improving patient outcomes. Currently, we are in an ‘early adopter’ phase of this technology and this paper reviews the rationale, methodology, optimal case selection, and limitations of robotic-assisted coronary intervention. Full article
(This article belongs to the Special Issue Advances in Interventional Cardiology and Vascular Medicine)
Show Figures

Figure 1

Back to TopTop